Combining the OVT with CTLA-4 blockade could complement the effects of poor tumor targeting through the selective replication ability of OVs in tumor cells and thus dramatically boost anti-tumor therapeutic efficacy [14]. This evidence concerns the gene CTLA4 and neoplasm.